Pfizer Inc. posted fourth-quarter earnings and a forecast for 2017 that were both short of analysts’ estimates, as the drugmaker said it will lose billions of dollars in revenue as products lose exclusive sales rights. Revenue in 2017 will be $52 billion to $54 billion, Pfizer said in a statement Tuesday, compared with the $54.3 billion average of analysts’ estimates compiled by Bloomberg.